Spirulina.Guru

Science

Spirulina and hypermobility syndrome.

Hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) involve connective tissue matrix dysfunction, chronic pain, fatigue, and frequent co-occurrence of POTS (postural orthostatic tachycardia syndrome) and MCAS (mast cell activation syndrome). Spirulina contains several micronutrients relevant to connective tissue synthesis — but MCAS overlap requires an ultra-slow introduction protocol, and POTS overlap has specific hydration and sodium implications.

hEDS connective tissue mechanism

  • Extracellular matrix dysfunction: hEDS is characterised by abnormal collagen cross-linking (specific gene undetermined in most cases, unlike classical EDS with COL5A1/2 mutations). The extracellular matrix in tendons, ligaments, skin, and vascular walls is insufficiently rigid, producing joint hypermobility, chronic subluxations, skin hyperextensibility, and visceral fragility.
  • Neurogenic inflammation and mast cell activation: Substance P and CGRP from nociceptive neurons in abnormally stressed connective tissue activate mast cells in the local tissue. Many hEDS patients meet diagnostic criteria for MCAS — a clinically significant overlap that directly affects spirulina introduction protocol.
  • Collagen synthesis requirements: Collagen is a proline/hydroxyproline-rich protein. Prolyl hydroxylase (converting proline to hydroxyproline for triple helix stability) requires iron as cofactor and vitamin C as electron donor. Iron deficiency and vitamin C deficiency both impair collagen synthesis. Spirulina provides iron (2–4 mg/5 g) and some vitamin C (approximately 1–3 mg/5 g — modest; pair with dietary vitamin C sources for maximum benefit).

MCAS overlap: the critical introduction protocol

  • Approximately 50–70% of hEDS patients meet MCAS criteria. Spirulina is a biological product and a potential MCAS trigger (see MCAS article for full details). The protocol for hEDS with MCAS overlap: start at 0.1 g/day, increase by 0.1 g every 5–7 days, monitoring 24–48h for any mast cell-related symptoms (flushing, urticaria, GI cramping, headache). Target dose may be 1–2 g/day maximum in severe MCAS rather than 3–5 g/day.
  • Antihistamines (cetirizine, fexofenadine, loratadine): no pharmacokinetic interaction with spirulina. H2 blockers (famotidine): no interaction. Ketotifen: no interaction. These are the standard MCAS medications and do not affect spirulina use.

POTS overlap: hydration and sodium

  • POTS management relies on high fluid intake (2–3 L/day) and increased sodium (5–10 g/day in some protocols) to expand plasma volume and reduce orthostatic tachycardia. Spirulina’s sodium content is low (100–200 mg/10 g) and does not contribute meaningfully to POTS sodium protocols. Spirulina shots in 150–200 ml of water are a practical way to take spirulina while contributing to POTS hydration targets.
  • POTS medications: fludrocortisone (mineralocorticoid), propranolol, ivabradine, midodrine — no pharmacokinetic interaction with spirulina for any of these. Propranolol is CYP2D6/1A2 substrate; no documented spirulina interaction.

Iron in hEDS: ferritin target

  • Iron deficiency is extremely common in hEDS patients — partly due to the female demographic predominance, heavy periods (common in hEDS from uterine and vascular fragility), GI malabsorption from dysmotility, and low-calorie diets from gastroparesis. Iron deficiency worsens fatigue (the dominant symptom in hEDS), worsens POTS (iron required for sympathetic nervous system catecholamine synthesis), and impairs collagen synthesis (prolyl hydroxylase).
  • Target ferritin for hEDS with fatigue and POTS: >70 µg/L (the same target as for RLS and alopecia areata). Check transferrin saturation to confirm genuine deficiency in the presence of any inflammatory markers.

Zinc for connective tissue

  • Zinc is a cofactor for matrix metalloproteinases (MMPs, which remodel the extracellular matrix) and for collagen cross-linking enzymes. Adequate zinc supports appropriate collagen remodelling rather than the disorganised, lax matrix characteristic of hEDS. Spirulina provides 0.5–1.5 mg zinc/5 g — a modest but relevant contribution alongside dietary zinc sources.

Practical guidance

  • hEDS without MCAS: 3–5 g/day; no specific NK or immunosuppression concerns; iron + zinc + protein relevant to connective tissue
  • hEDS with MCAS overlap: start at 0.1 g/day; increase 0.1 g every 5–7 days; monitor 24–48h; maximum tolerated dose may be 1–3 g/day; no MCAS medication interactions
  • hEDS with POTS: standard dose; use spirulina shots as part of POTS hydration protocol; no interaction with POTS medications
  • Check ferritin + transferrin saturation; target >70 µg/L; significant deficiency requires dedicated iron therapy alongside spirulina

Related reading

Get the weekly digest

Curated science, recipes, and brand intel — once a week, no spam, unsubscribe in one click.